Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
· New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients1
· Results from a pooled analysis of two Phase 3 studies, show that patients treated with Cosentyx (n=477) had a faster time to complete resolution of enthesitis than those receiving placebo (n=235)2
· Both Cosentyx 300 mg and 150 mg provided sustained improvements in signs and symptoms of psoriatic arthritis at two years in patients with or without enthesitis2
· Results strengthen unique position of Cosentyx as a rapid and long-lasting complete treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis with over 250,000 patients treated worldwide3
Basel, October 10th, 2019 – Novartis, a leader in rheumatology and immuno-dermatology, today announced results for Cosentyx from a pooled-analysis that shows sustained improvement in signs and symptoms of psoriatic arthritis, particularly for American College of Rheumatology 50 (ACR50), and Psoriasis Area and Severity Index (PASI) severity endpoints.
“We are pleased that the data show rapid and sustained improvement across two years in the signs and symptoms of psoriatic arthritis with Cosentyx, regardless of whether patients have enthesitis or not,” said Eric Hughes, Global Development Unit Head, Immunology, Hepatology & Dermatology. “Psoriatic arthritis is complex with multiple manifestations driving patient symptoms including enthesitis, which is often associated with more severe disease. At Novartis we are striving to reimagine care in immuno-dermatology and across all manifestations of psoriatic disease to support patients and help them achieve improved quality of life.”
The abstract, being presented at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) in Madrid, shows that ACR 50, PASI 90 and Quality of life response with secukinumab at month 4 in patients with and without enthesitis is sustained up to 2 years.